Skip to main content
. 2022 Aug 1;36(9):2180–2188. doi: 10.1038/s41375-022-01651-9

Fig. 5. IGF2BP2 knockdown significantly decreases leukemia burden in the human T-ALL xenograft.

Fig. 5

A Kaplan–Meier survival curves of Jurkat xenografts in each group as indicated (n = 7 for each group). Survival of KD or LCV2 mice (orange and green lines) are compared with p value provided as shown (log-rank test). B Representative spleen and bone images of mice carrying Jurkat cells with or without IGF2BP2 expression. C Human CD45+ cells from bone marrow, spleen and peripheral blood were analyzed by flow cytometry. Data from five individual mice were plotted and shown on the right. Data are mean ± SD values. *P < 0.05; **P < 0.01; ***P < 0.001.